Nongnuch SirachainanUsanarat AnurathapanAmpaiwan ChuansumritDuantida SongdejPakawan WongwerawattanakoonSakara HutspardolPimpun KitpokaMahidol UniversitySrinakharinwirot University2018-10-192018-10-192013-12-01Pediatrics International. Vol.55, No.6 (2013)1442200X132880672-s2.0-84890443282https://repository.li.mahidol.ac.th/handle/20.500.14594/32059Nine patients with chronic immune thrombocytopenia and platelet counts <20 × 109/L, with a median age of 7.8 (3.8-15.5) years, received three phases of 10 mcg/kg/dose of intramuscular anti-D. Phase 1 was anti-D daily for 5 days, followed by phase 2, anti-D weekly for 12 weeks and withheld when platelet counts ≥20 × 109/L, and then phase 3 was anti-D once every 2 weeks for 24 weeks. According to the International Working Group criteria, in phase 1, 66.7% of patients responded to the treatment. In phases 2 and 3, 11.1% (0-41.7%) and 7.7% (0-33.3%) of total episodes of follow up, respectively, responded to the treatment. Therefore, intramuscular anti-D given at a dose of 10 mcg/kg for 5 days is an alternative method to raise platelet counts in chronic immune thrombocytopenia children with severe thrombocytopenia where the intravenous form of anti-D is not available. © 2013 Japan Pediatric Society.Mahidol UniversityMedicineArticleSCOPUS10.1111/ped.12179